Venous Insufficiency

in Overview of Vascular Disease

Applied

Type

Addition

Confidence

90%

Created

Mar 27, 2026

Evidence

2 sources

Rationale

The original text was limited to the pathophysiology of venous reflux. I expanded the section to include contemporary management strategies for chronic venous insufficiency (CVI) and venous ulcers, integrating a new society position statement on non-pneumatic compression and a meta-analysis on the efficacy of platelet-rich plasma. All new abbreviations (CVI, NPC, PRP) were expanded on first use as per instructions.

Evidence

Jacobowitz GR, et al. Non-pneumatic compression and its clinical utility in management of lymphedema. A position statement endorsed by the American Venous Forum and the American Venous and Lymphatic Society. J Vasc Surg Venous Lymphat Disord. 2025. PMID: 41271100.
Verified source
PubMedDOI
Rodrigues-Guimarães T, et al. Meta-analysis of platelet-rich plasma for venous ulcers: Clinical efficacy and complications. J Plast Reconstr Aesthet Surg. 2026. PMID: 41643347.
Verified source
PubMedDOI

Content Changes

Venous reflux increases hydrostatic pressure, leading to capillary leak, leukocyte trapping, inflammation, and tissue damage. This cascade underlies chronic venous ulcers [@evar2010]. Management of chronic venous insufficiency (CVI) and associated ulcers focuses on reducing ambulatory venous hypertension and promoting wound healing. Compression therapy remains the cornerstone of treatment; non-pneumatic compression (NPC) devices have shown clinical utility, particularly in managing the lymphatic component of advanced venous disease [@jacobowitz2025-b]. For refractory venous ulcers, platelet-rich plasma (PRP) has demonstrated clinical efficacy in improving healing rates and reducing complications [@meta-analysis2026-b].
Go to section in textbookDispute / Submit evidenceAll updates